| Ytd | 69.20% | |
| 1y | 205.78% |
| Open | 13.30 | Prev Close | 13.30 | Low | 12.57 | High | 13.53 | Mkt Cap | 663.39M |
| Vol | 1.07M | Avg Vol | 860.02K | EPS | -2.57 | P/E | N/A | Forward P/E | -1.79 |
| Beta | 2.80 | Short Ratio | 9.86 | Inst. Own | 115.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 9.75 | 200-d Avg | 9.44 | 1yr Est | 42.64 |
FDMT News
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT
4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 ove
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT,
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperfo
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.43 per share which beat th
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology c
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperfo
Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight an
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology co
4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost
RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperf
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading.
During Thursday's session, 108 stocks hit new 52-week highs.
Upgrades
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday afte
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite gaining more than 150 points. Here i
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q
On Friday, 422 stocks made new 52-week lows.
On Tuesday, 540 companies set new 52-week lows.
On Tuesday, 123 stocks made new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 431 companies hit new 52-week lows.
On Monday, 466 companies hit new 52-week lows.